KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to $42.6 million.

  • Emergent BioSolutions' Other Non-Current Liabilities rose 1899.44% to $42.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.6 million, marking a year-over-year increase of 1899.44%. This contributed to the annual value of $39.1 million for FY2024, which is 3529.41% up from last year.
  • Emergent BioSolutions' Other Non-Current Liabilities amounted to $42.6 million in Q3 2025, which was up 1899.44% from $39.5 million recorded in Q2 2025.
  • In the past 5 years, Emergent BioSolutions' Other Non-Current Liabilities ranged from a high of $69.5 million in Q4 2021 and a low of $23.4 million during Q2 2023
  • In the last 5 years, Emergent BioSolutions' Other Non-Current Liabilities had a median value of $39.5 million in 2025 and averaged $42.5 million.
  • As far as peak fluctuations go, Emergent BioSolutions' Other Non-Current Liabilities plummeted by 6000.0% in 2023, and later surged by 5369.65% in 2025.
  • Over the past 5 years, Emergent BioSolutions' Other Non-Current Liabilities (Quarter) stood at $69.5 million in 2021, then plummeted by 40.29% to $41.5 million in 2022, then tumbled by 30.36% to $28.9 million in 2023, then surged by 35.29% to $39.1 million in 2024, then rose by 8.95% to $42.6 million in 2025.
  • Its last three reported values are $42.6 million in Q3 2025, $39.5 million for Q2 2025, and $35.4 million during Q1 2025.